Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and tolerability of MS-R001 at escalating doses in patients with diabetic macular edema secondary to diabetic retinopathy

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Santen Inc.
• Collaborator: MacuSight, Inc.
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria include but are not limited to:

• Diagnosed with diabetes mellitus

• Visual acuity of 20/40 to 20/200 in study eye

Exclusion Criteria include but are not limited to:

• Any other ocular disease that could compromise vision in the study eye

• Intraocular surgery of the study eye within 90 days prior to study start

• Capsulotomy of the study eye within 30 days prior to study start